“Small Molecule Modulators of MET Kinase for Treatment of Human Malignancies.” AACR, Washington, DC 2010.
DCC-2721 - solid tumor (cMET inhibitor)
Deciphera’s DCC-2721 is currently available for worldwide licensure.
DCC-2721 is in preclinical development. This candidate exhibits high potency and selectivity for inhibiting cMET kinase and the activation loop oncogenic cMET mutants. Inhibition of cMET kinase blocks a key mechanism that causes cancer invasiveness and metastasis. High potency has also been demonstrated in cellular studies of cancer cell proliferation, motility and invasiveness. DCC-2721 has been optimized for oral administration and has demonstrated efficacy in cMET cancer animal models.
- DCC-2721 blocks cMET driven cancer growth and invasiveness
- DCC-2721 potently inhibits D1246 and Y1248 mutant forms of cMET activated in certain cancers.
Publications and Presentations